Access Program Information
The purpose of this study is to provide expanded access of patisiran to patients with
hereditary transthyretin-mediated amyloidosis (hATTR).
Alnylam Pharmaceuticals – Amyloidosis, Hereditary, Transthyretin-Related
Rare Disease: